Christopher E. Ormsby

Christopher E. Ormsby

Auto-generated profile, based on publicly available information

Christopher E. Ormsby

Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER)

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LILuis Iniguez
Luis Iniguez
MRMiguel de Mulder Rougvie
Miguel de Mulder Rougvie
NSNathaniel Stearrett
Nathaniel Stearrett
RJRichard B. Jones
Richard B. Jones
COChristopher E. Ormsby
Christopher E. Ormsby
MBMatthew Bendall
Matthew Bendall

29 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DZDaniela De la Rosa Zamboni
Daniela De la Rosa Zamboni
JVJoel Armando Vazquez-Perez
Joel Armando Vazquez-Perez
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
ACAna Paola Carranco-Arenas
Ana Paola Carranco-Arenas
COChristopher E. Ormsby
Christopher E. Ormsby
GRGustavo Reyes-Terán
Gustavo Reyes-Terán
When the A(H1N1)pdm09 pandemic influenza virus moved into the post-pandemic period, there was a worldwide predominance of the seasonal influenza A(H3N2) and B viruses. However, A(H1N1)pdm09 became the prevailing subtype in the 2011–2012 influenza season in Mexico and most of Central America. During this season, we collected nasopharyngeal swabs of individuals presenting with influenza-like illness at our institution in Mexico City. Samples were tested for seasonal A(H3N2) and B influenza viruses, as well as A(H1N1)pdm09 by real-time reverse transcription–polymerase chain reaction. Of 205 samples tested, 46% were positive to influenza, all of them A(H1N1)pdm09. The clinical characteristics of patients showed a similar pattern to the 2009 pandemic cases. Using next generation sequencing, we obtained whole genome sequences of viruses from 4 different patients, and in 8 additional viruses we performed partial Sanger sequencing of the HA segment. Non-synonymous changes found in the Mexican isolates with respect to the prototype isolate H1N1 (A/California/04/2009) included HA S69T, K163R and N260D unique to 2012 Mexican and North American isolates and located within or adjacent to HA antigenic sites; HA S143G, S185T, A197T and S203T previously reported in viruses from the 2010–2011 season, located within or adjacent to HA antigenic sites; and HA E374K located in a relevant site for membrane fusion. All Mexican isolates had an oseltamivir-sensitive genotype. Phylogenetic analysis with all 8 influenza gene segments showed that 2012 Mexican sequences formed a robust, distinct cluster. In all cases, 2012 Mexican sequences tended to group with 2010–2011 Asian and European sequences, but not with 2009 Mexican sequences, suggesting a possible recent common ancestor between these latter regions and the 2012 Mexican viruses. It remains to be defined if these viral changes represent an important antigenic drift that would enable viral immune evasion and/or affect influenza vaccine effectiveness.

18 March 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Open access
DCDennis C. Copertino
Dennis C. Copertino
BLBruno C. Casado Lima
Bruno C. Casado Lima
RDRodrigo R. R. Duarte
Rodrigo R. R. Duarte
TPTimothy R Powell
Timothy R Powell
COChristopher E. Ormsby
Christopher E. Ormsby
DNDouglas Nixon
Douglas Nixon
COVID-19 is the disease caused by SARS-CoV-2 which has led to 2,643,000 deaths worldwide, a number which is rapidly increasing. Urgent studies to identify new antiviral drugs, repurpose existing drugs, or identify drugs that can target the overactive immune response are ongoing. Antiretroviral drugs (ARVs) have been tested in past human coronavirus infections, and also against SARS-CoV-2, but a trial of lopinavir and ritonavir failed to show any clinical benefit in COVID-19. However, there is limited data as to the course of COVID-19 in people living with HIV, with some studies showing a decreased mortality for those taking certain ARV regimens. We hypothesized that ARVs other than lopinavir and ritonavir might be responsible for some protection against the progression of COVID-19. Here, we used chemoinformatic analyses to predict which ARVs would bind and potentially inhibit the SARS-CoV-2 main protease (Mpro) or RNA-dependent-RNA-polymerase (RdRp) enzymes in silico. The drugs predicted to bind the SARS-CoV-2 Mpro included the protease inhibitors atazanavir and indinavir. The ARVs predicted to bind the catalytic site of the RdRp included Nucleoside Reverse Transcriptase Inhibitors, abacavir, emtricitabine, zidovudine, and tenofovir. Existing or new combinations of antiretroviral drugs could potentially prevent or ameliorate the course of COVID-19 if shown to inhibit SARS-CoV-2 in vitro and in clinical trials. Further studies are needed to establish the activity of ARVs for treatment or prevention of SARS-CoV-2 infection . Communicated by Ramaswamy H. Sarma

1 December 2020 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
IOIván Osuna-Padilla
Iván Osuna-Padilla
AAAdriana Aguilar-Vargas
Adriana Aguilar-Vargas
NRNADIA RODRIGUEZ
NADIA RODRIGUEZ
ARAndrea Villazón-De la Rosa
Andrea Villazón-De la Rosa
IOIgnacio Osuna-Ramírez
Ignacio Osuna-Ramírez
GRGustavo Reyes-Terán
Gustavo Reyes-Terán